Amneal Pharmaceuticals, Inc. (AMRX) FY2026 Q2 Statement of Cash Flows

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
Amneal Pharmaceuticals, Inc. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Borrowings on revolving credit facilities → financing reconciliation: $100,000,000.00Proceeds from exercise of stock options → financing reconciliation: $42,000.00financing reconciliation → Net cash from financing activities: $79,361,000.00financing reconciliation → Tax and other distributions to non-controlling interests: $13,920,000.00financing reconciliation → Payments of principal on debt, revolving credit facilities, financing leases and other: $6,185,000.00financing reconciliation → Acquisition of non-controlling interest: $400,000.00financing reconciliation → Employee payroll tax withholding on restricted stock unit and performance stock unit vesting: $176,000.00Net cash used in investing activities → investing reconciliation: $122,742,000.00investing reconciliation → Acquisition of intangible assets: $77,150,000.00investing reconciliation → Purchases of property, plant and equipment: $30,697,000.00investing reconciliation → Deposits for future acquisition of property, plant and equipment: $14,895,000.00Net cash used in operating activities → operating reconciliation: $21,244,000.00Net income → operating reconciliation: $69,614,000.00Accounts payable, accrued expenses and other liabilities → operating reconciliation: $66,660,000.00Depreciation and amortization → operating reconciliation: $47,800,000.00Inventory provision → operating reconciliation: $31,604,000.00Stock-based compensation → operating reconciliation: $10,392,000.00Amortization of debt issuance costs and discount → operating reconciliation: $4,064,000.00Reclassification of cash flow hedge → operating reconciliation: $2,910,000.00Unrealized foreign currency loss (gain) → operating reconciliation: $2,280,000.00Other operating charges and credits, net → operating reconciliation: $1,600,000.00Related party receivables → operating reconciliation: $81,000.00operating reconciliation → Trade accounts receivable, net: $169,778,000.00operating reconciliation → Inventories: $69,191,000.00operating reconciliation → Prepaid expenses, other current assets and other assets: $10,750,000.00operating reconciliation → Related party payables: $8,530,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $204,408,000.00Net cash from financing activities → Cash sources and uses: $79,361,000.00Cash sources and uses → Exchange-rate effect: $164,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $139,619,000.00Cash sources and uses → Net cash used in investing activities: $122,742,000.00Cash sources and uses → Net cash used in operating activities: $21,244,000.00Net income: $69,614,000.00Net income+$69.61 MDepreciation and amortization: $47,800,000.00Depreciation and amortization+$47.80 MUnrealized foreign currency loss (gain): $2,280,000.00Unrealized FX gain & loss+$2.28 MAmortization of debt issuance costs and discount: $4,064,000.00Debt cost amortization+$4.06 MStock-based compensation: $10,392,000.00Stock-based compensation+$10.39 MInventory provision: $31,604,000.00Inventory write-downs+$31.60 MOther operating charges and credits, net: $1,600,000.00Other non-cash items+$1.60 MTrade accounts receivable, net: -$169,778,000.00Accounts receivable−$169.78 MInventories: -$69,191,000.00Inventories−$69.19 MPrepaid expenses, other current assets and other assets: -$10,750,000.00Prepaid & other assets−$10.75 MRelated party receivables: $81,000.00Related party receivables+$81.00 KAccounts payable, accrued expenses and other liabilities: $66,660,000.00Payables & accrued liabilities+$66.66 MRelated party payables: -$8,530,000.00Due to related parties−$8.53 MReclassification of cash flow hedge: $2,910,000.00Cash flow hedge reclassification+$2.91 MLoss on refinancing: $0.00Net cash used in operating activities: -$21,244,000.00. Cash required to fund net payments.Operating cash−$21.24 Moperating reconciliation: $258,249,000.00Payments of principal on debt, revolving credit facilities, financing leases and other: -$6,185,000.00Debt, credit & lease repaid−$6.19 MProceeds from issuance of debt: $0.00Payments of deferred financing and refinancing costs: $0.00Borrowings on revolving credit facilities: $100,000,000.00Credit line borrowings+$100.00 MProceeds from exercise of stock options: $42,000.00Stock option exercises+$42.00 KEmployee payroll tax withholding on restricted stock unit and performance stock unit vesting: -$176,000.00Stock-award tax withholding−$176.00 KTax and other distributions to non-controlling interests: -$13,920,000.00Paid to noncontrolling interests−$13.92 MProceeds from alliance party: $0.00Acquisition of non-controlling interest: -$400,000.00Paid to noncontrolling interests−$400.00 KNet cash from financing activities: $79,361,000.00Financing cash+$79.36 Mfinancing reconciliation: $100,042,000.00Purchases of property, plant and equipment: -$30,697,000.00PP&E purchases−$30.70 MAcquisition of intangible assets: -$77,150,000.00Intangible asset purchases−$77.15 MDeposits for future acquisition of property, plant and equipment: -$14,895,000.00PP&E acquisition deposits−$14.90 MProceeds from sale of property, plant and equipment: $0.00Net cash used in investing activities: -$122,742,000.00. Cash required to fund net payments.Investing cash−$122.74 Minvesting reconciliation: $122,742,000.00Cash sources and uses: $283,769,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $204,408,000.00Beginning cash$204.41 MEnding cash: Cash, cash equivalents, and restricted cash: $139,619,000.00Ending cash$139.62 MExchange-rate effect: -$164,000.00FX effect−$164.00 KCASH RECONCILIATIONFinancingflowsInvestingflowsOperatingflowsFree cash flow−$51.94 MOperating cash − cash spent on PP&ECash flow / Net income−0.31×Operating cash flow ÷ net incomeNet cash change−$64.79 MEnding cash − beginning cash
Chart details

Amneal Pharmaceuticals, Inc. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
204,408,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
negative 21,244,000 US dollars. Net cash used.
Net income
69,614,000 US dollars
Depreciation and amortization
47,800,000 US dollars
Unrealized foreign currency loss (gain)
2,280,000 US dollars
Amortization of debt issuance costs and discount
4,064,000 US dollars
Stock-based compensation
10,392,000 US dollars
Inventory provision
31,604,000 US dollars
Other operating charges and credits, net
1,600,000 US dollars
Trade accounts receivable, net
negative 169,778,000 US dollars
Inventories
negative 69,191,000 US dollars
Prepaid expenses, other current assets and other assets
negative 10,750,000 US dollars
Related party receivables
81,000 US dollars
Accounts payable, accrued expenses and other liabilities
66,660,000 US dollars
Related party payables
negative 8,530,000 US dollars
Reclassification of cash flow hedge
2,910,000 US dollars
Loss on refinancing
0 US dollars
Investing activities
negative 122,742,000 US dollars. Net cash used.
Purchases of property, plant and equipment
negative 30,697,000 US dollars
Acquisition of intangible assets
negative 77,150,000 US dollars
Deposits for future acquisition of property, plant and equipment
negative 14,895,000 US dollars
Proceeds from sale of property, plant and equipment
0 US dollars
Financing activities
79,361,000 US dollars. Net cash provided.
Payments of principal on debt, revolving credit facilities, financing leases and other
negative 6,185,000 US dollars
Proceeds from issuance of debt
0 US dollars
Payments of deferred financing and refinancing costs
0 US dollars
Borrowings on revolving credit facilities
100,000,000 US dollars
Proceeds from exercise of stock options
42,000 US dollars
Employee payroll tax withholding on restricted stock unit and performance stock unit vesting
negative 176,000 US dollars
Tax and other distributions to non-controlling interests
negative 13,920,000 US dollars
Proceeds from alliance party
0 US dollars
Acquisition of non-controlling interest
negative 400,000 US dollars
Operating adjustment reconciliation
258,249,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
100,042,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
122,742,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 164,000 US dollars
Ending cash on Jun 30, 2026
139,619,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
283,769,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 64,789,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
−0.31×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
negative 21,244,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
30,697,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
negative 51,941,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income or operating cash is negative. The full signed reconciliation is retained: losses remain deductions, and any negative operating-cash total enters the junction from the cash pool. No positive direct-income connection is implied.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: negative 21,244,000 US dollars minus 30,697,000 US dollars equals negative 51,941,000 US dollars.
Amneal Pharmaceuticals, Inc. (AMRX) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!